Search results for: “Macular degeneration”
-
What Kind of Doctor Do I Need to See
Do you know the difference between an optician, an optometrist, an ophthalmologist, and a retina specialist, and which one you should see for various eye issues? Don’t worry, you’re not alone. Let us explain. Optician An optician is not a doctor. Therefore they cannot offer an eye exam, any diagnoses, or medications. Their job is
-
Demetrios Vavvas
Demetrios Vavvas, MD, PhD, Co-Director of the Ocular Regenerative Medical Institute, Harvard Medical School As a clinician scientist, Dr. Vavvas is a full-time member of the Mass. Eye and Ear Retina Service and has a highly productive translational research laboratory. His clinical interests focus on diabetic retinopathy, ocular tumors, and the “dry” form of age-related
-
Bonnielin Swenor
Bonnielin Swenor, PhD, MPH, Johns Hopkins School of Nursing Dr. Swenor and The Swenor Research Group seek to improve the health of people with visual impairments. Dr. Swenor is motivated by personal experience living with a visual disability similar to macular degeneration. Her focus is on three interrelated areas: Vision and Aging: examining the impact of
-
Johanna Seddon
Johanna Seddon, MD, ScM, Director of Retina, Department of Ophthalmology and Visual Science & Director of the Macular Degeneration Center of Excellence, University of Massachusetts Medical School Dr. Seddon pioneered the field of epidemiology in ophthalmology, initiated studies of genes associated with macular degeneration, and is widely recognized for her groundbreaking research on lifestyle factors (smoking,
-
Jason Miller
Jason Miller, MD, PhD, University of MichiganMentor: Debra Thompson, PhD Dr. Miller’s research program seeks to establish primary retinal pigment epithelium (RPE) culture models of dry age-related macular degeneration (AMD) as a platform for testing therapeutic interventions. RPE cells are those most affected in AMD. With his 2020 AMDF/FFS Post-Doctoral Award ($11,250), he sought to
-
Aparna Lakkaraju
Aparna Lakkaraju, PhD, Associate Professor, University of California, San Francisco, School of Medicine Research in the Lakkaraju laboratory builds on fundamental insights from retinal cell biology to develop effective therapies for inherited and age-related macular degeneration (AMD). The initial site of injury in AMD is the retinal pigment epithelium (RPE), the tissue that nourishes and
-
Matthew Hunt
Matthew Hunt, University of Washington, SeattleMentor: Aaron Lee, MD, MSc With his 2020 AMDF/FFS Summer Student Fellowship ($1,250), Matthew sought to develop a real-world assessment of visual impairment in age-related macular degeneration in the anti-VEGF era using the AAO IRIS Registry.
-
Sabine Fuhrmann
Sabine Fuhrmann, PhD, Associate Professor, Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee Dr. Fuhrmann has a broad background in neurobiology, with specific training and expertise in neurodevelopment. Her long term objectives are to identify novel targets for therapeutic strategies to treat degenerative eye diseases of the retinal pigment epithelium (RPE), such as AMD. RPE cells
-
Shun-Yun Cheng
Shun-Yun Cheng, PhD student Department of Ophthalmology and Visual Sciences, University of Massachusetts Medical SchoolWith her 2019 AMDF/ARVO Travel Grant, Shun-Yun presented results from her study in which she proposed a new way of thinking about the origins of AMD: that photoreceptors may initiate damage to the layer of cells that nourish them, the retinal pigment
-
Michael Berry
Michael Berry II, PhD, Associate Professor, Molecular Biology and the Princeton Neuroscience Institute Co-Director, Program in Neuroscience, Princeton University (and CEO of Optimal Acuity Corp.) Dr. Berry’s lab seeks to expand our understanding of how neurons combine to carry out powerful computations and has discovered that the retina carries out a diverse set of surprisingly